Skip to main content
. 2017 Jan 20;176(5):743–749. doi: 10.1111/bjh.14465

Figure 1.

Figure 1

Progression‐free survival and overall survival in the Asian subpopulation (A and B, respectively). NE, not estimable; MPT, melphalan, prednisone, thalidomide; Rd cont, lenalidomide plus low‐dose dexamethasone until disease progression; Rd18, lenalidomide plus low‐dose dexamethasone for 18 cycles.